BioXcel Therapeutics Inc (FRA:BX2)
€ 1.892 0.006 (0.32%) Market Cap: 72.49 Mil Enterprise Value: 98.09 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 21/100

BioXcel Therapeutics Inc at UBS Global Healthcare Virtual Conference Transcript

May 25, 2021 / 06:00PM GMT
Release Date Price: €25.61 (+0.79%)
Colin Nigel Bristow
UBS Investment Bank, Research Division - Analyst

Well, good afternoon, and thank you, everyone for joining the virtual UBS Global Healthcare Conference. I'm Colin Bristow. I'm one of the biotech analysts here at UBS. And it's my pleasure to have with us today, BioXcel. Speaking on behalf of the company, we have Will Kane, the Chief Commercial Officer, and later for Q&A, we'll have Vince O'Neill, the Chief Medical Officer. So Will and Vince, thank you for joining us today.

Before we start, if anyone has a question, there is a question function available within this video app or feel free you e-mail me directly at [email protected] and I can try and fill the question for you.

And with that, Will, I'll hand it over to you now. Thanks.

William P. Kane
BioXcel Therapeutics, Inc. - Executive VP & Chief Commercial Officer

Sure. Thank you so much, Colin, and thank you for the opportunity this afternoon to talk about BioXcel Therapeutics. It's a great opportunity for me to share the evolving story and the key

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot